Home Monitoring Tech to Continue to Gain Steam in 2020
In a flash Q&A with MedTech Intelligence, Bob Terbrueggen, president and CEO of DxTerity gives some quick predictions of where health tech is headed in 2020.
MedTech Intelligence: Looking back at 2019, what were some of the most significant MedTech developments?
Bob Terbrueggen: 2019: CRISPR gene editing of human embryos and other applications
MTI: What MedTech breakthroughs are on the horizon for 2020?
Terbrueggen: 2020: Home monitoring of chronic disease combined with telehealth, wearables and precision medicine: The Apple Watch made a big splash with its ability to spot cardiac arrhythmias, and companies like Livongo have started to demonstrate the ability to more effectively manage diabetes patients from home. 2020 should be the year that home monitoring breaks through and goes beyond diabetes to everyday healthcare. Advances in 5G and the Internet of Everything will be combined with genomics to enable effective monitoring in autoimmune and cancer [treatment]. [Additional breakthroughs include] liquid biopsy based on ctDNA as well as gene expression monitoring of therapy response.
MTI: What industry challenges are ahead?
Terbrueggen: Patient privacy, HIPAA compliance, regulatory clearance and reimbursement.
Related Articles
-
Tonometry-derived features showed superior performance compared to other feature groups and baselines, while younger and normotensive subjects had the most consistent readings across all feature groups.
-
“The solution provider that builds the device and creates the algorithm should consider integration and accountability among multiple other challenges. But meeting the needs of the third element in the equation, the doctors, is key.”
-
New data presented at the Technology and Heart Failure Therapeutics (THT) Conference showed that hemodynamic monitoring can slow the progression of heart failure in patients with reduced ejection fraction.
-
“M.I.Tech is an innovator in nonvascular stent development, with product offerings that complement our existing stent portfolio.”
